Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers
暂无分享，去创建一个
M. Mesulam | L. Petrucelli | R. Petersen | B. Boeve | D. Knopman | M. Murray | D. Dickson | J. Parisi | R. Caselli | L. Grinberg | W. Seeley | E. Bigio | S. Weintraub | A. Kertesz | M. Heckman | A. Karydas | T. Beach | G. Hsiung | Z. Wszolek | N. Graff-Radford | I. Mackenzie | E. Finger | M. Strong | K. Hatanpaa | M. Baker | C. White | M. Neumann | K. Josephs | C. Lippa | K. Boylan | M. Blitterswijk | Patricia H. Brown | H. Stewart | Bianca Mullen | R. Rademakers | B. Miller | M. Dejesus‐Hernandez | B. Miller | D. Knopman
[1] Kevin F. Bieniek,et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia , 2014, Acta Neuropathologica.
[2] J. Trojanowski,et al. Therapeutic modulation of eIF2α-phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models , 2013, Nature Genetics.
[3] Kevin F. Bieniek,et al. C9ORF72 repeat expansions in cases with previously identified pathogenic mutations , 2013, Neurology.
[4] L. Petrucelli,et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study , 2013, The Lancet Neurology.
[5] D. Fan,et al. ATXN2 CAG repeat expansions increase the risk for Chinese patients with amyotrophic lateral sclerosis , 2013, Neurobiology of Aging.
[6] P. Svenningsson,et al. De Novo Mutations in Ataxin-2 Gene and ALS Risk , 2013, PloS one.
[7] Oliver D. King,et al. Stress granules as crucibles of ALS pathogenesis , 2013, The Journal of cell biology.
[8] G. Logroscino,et al. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis , 2012, Neurology.
[9] Y. Parman,et al. ATXN2 and Its Neighbouring Gene SH2B3 Are Associated with Increased ALS Risk in the Turkish Population , 2012, PloS one.
[10] B. Castellotti,et al. ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling , 2012, Neurobiology of Aging.
[11] P. Rossini,et al. Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease , 2012, Neurology.
[12] E. Cuppen,et al. NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. , 2012, Human molecular genetics.
[13] P. Deyn,et al. Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts , 2012, Neurobiology of Aging.
[14] C. Barnes,et al. SMN1 gene duplications are associated with sporadic ALS , 2012, Neurology.
[15] R. Krüger,et al. The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect , 2012, Neurobiology of Disease.
[16] David Heckerman,et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.
[17] Bruce L. Miller,et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.
[18] P. Pan,et al. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis , 2011, Neurobiology of Aging.
[19] V. Meininger,et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. , 2011, Archives of neurology.
[20] C. Angelini,et al. ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion , 2011, Neurology.
[21] B. Miller,et al. Ataxin-2 repeat-length variation and neurodegeneration. , 2011, Human molecular genetics.
[22] B. Dubois,et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2 , 2011, Neurology.
[23] A. Brusco,et al. ATXN-2 CAG repeat expansions are interrupted in ALS patients , 2011, Human Genetics.
[24] P. Andersen,et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. , 2011, Human molecular genetics.
[25] John Q. Trojanowski,et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS , 2010, Nature.
[26] B. Giraudeau,et al. SMN1 gene, but not SMN2, is a risk factor for sporadic ALS , 2006, Neurology.
[27] L. H. van den Berg,et al. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS , 2005, Neurology.
[28] C. Andres,et al. Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis , 2002, Annals of neurology.
[29] F. Baas,et al. Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS , 2001, Neurology.
[30] L. H. van den Berg,et al. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis? , 2014, Trends in molecular medicine.